Emtricitabine rilpivirine tenofovir adverse reactions

Revision as of 05:03, 10 January 2014 by Mohamed Moubarak (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Emtricitabine rilpivirine tenofovir
COMPLERA® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]

Adverse Reactions

ADVERSE REACTIONS

The following adverse drug reactions are discussed in other sections of the labeling:

  • Lactic Acidosis/Severe Hepatomegaly with Steatosis [See Boxed Warning, Warnings and Precautions].
  • Severe Acute Exacerbations of Hepatitis B [See Boxed Warning, Warnings and Precautions].
  • New Onset or Worsening Renal Impairment [See Warnings and Precautions].
  • Depressive Disorders [See Warnings and Precautions].
  • Hepatotoxicity [See Warnings and Precautions].
  • Bone Effects of Tenofovir DF [See Warnings and Precautions].
  • Immune Reconstitution Syndrome [See Warnings and Precautions].[1]

References

  1. "COMPLERA (EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.]". Text " accessdate" ignored (help)

Adapted from the FDA Package Insert.